These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 31753002)

  • 21. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
    Du J; Zhang Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
    Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
    Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
    Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
    Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation.
    Jia H; Wang Z; Wang Y; Liu Y; Dai H; Tong C; Guo Y; Guo B; Ti D; Han X; Yang Q; Wu Z; Han W
    J Hematol Oncol; 2019 Jun; 12(1):57. PubMed ID: 31182121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
    Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
    J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Fulminant hepatic failure with hepatitis B virus reactivation after rituximab treatment in a patient with resolved hepatitis B].
    Chung SM; Sohn JH; Kim TY; Yoo KD; Ahn YW; Bae JH; Jeon YC; Choi JH
    Korean J Gastroenterol; 2010 Apr; 55(4):266-9. PubMed ID: 20389182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
    Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
    J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
    Spiegel JY; Patel S; Muffly L; Hossain NM; Oak J; Baird JH; Frank MJ; Shiraz P; Sahaf B; Craig J; Iglesias M; Younes S; Natkunam Y; Ozawa MG; Yang E; Tamaresis J; Chinnasamy H; Ehlinger Z; Reynolds W; Lynn R; Rotiroti MC; Gkitsas N; Arai S; Johnston L; Lowsky R; Majzner RG; Meyer E; Negrin RS; Rezvani AR; Sidana S; Shizuru J; Weng WK; Mullins C; Jacob A; Kirsch I; Bazzano M; Zhou J; Mackay S; Bornheimer SJ; Schultz L; Ramakrishna S; Davis KL; Kong KA; Shah NN; Qin H; Fry T; Feldman S; Mackall CL; Miklos DB
    Nat Med; 2021 Aug; 27(8):1419-1431. PubMed ID: 34312556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection.
    Yang C; Xie M; Zhang K; Liu H; Liang A; Young KH; Qian W
    Leukemia; 2020 Nov; 34(11):3055-3059. PubMed ID: 32533094
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
    Viganò M; Mangia G; Lampertico P
    Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.
    Mak JWY; Law AWH; Law KWT; Ho R; Cheung CKM; Law MF
    World J Gastroenterol; 2023 Sep; 29(33):4942-4961. PubMed ID: 37731995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.
    Drumheller B; Gebre K; Lockhart B; Margolskee E; Obstfeld A; Paessler M; Pillai V
    Int J Lab Hematol; 2022 Aug; 44(4):750-758. PubMed ID: 35419923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.
    An J; Lim YS; Kim GA; Han SB; Jeong W; Lee D; Shim JH; Lee HC; Lee YS
    BMC Gastroenterol; 2017 Jan; 17(1):15. PubMed ID: 28103819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.
    Sanchez MJ; Buti M; Homs M; Palacios A; Rodriguez-Frias F; Esteban R
    J Hepatol; 2009 Dec; 51(6):1091-6. PubMed ID: 19836097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
    Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
    Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
    N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review.
    Zheng J; Xiao Y; Wu XQ; Xiao QZ; Feng C; Gao KB
    Front Immunol; 2023; 14():1098815. PubMed ID: 36798130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.